These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24623105)

  • 1. United States Food and Drug Administration and Department of Defense shelf-life extension program of pharmaceutical products: progress and promise.
    Khan SR; Kona R; Faustino PJ; Gupta A; Taylor JS; Porter DA; Khan M
    J Pharm Sci; 2014 May; 103(5):1331-6. PubMed ID: 24623105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability profiles of drug products extended beyond labeled expiration dates.
    Lyon RC; Taylor JS; Porter DA; Prasanna HR; Hussain AS
    J Pharm Sci; 2006 Jul; 95(7):1549-60. PubMed ID: 16721796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability analysis for drugs with multiple active ingredients.
    Chow SC; Shao J
    Stat Med; 2007 Mar; 26(7):1512-7. PubMed ID: 16955533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Importance and Quality Evaluation of Drug Delivery Autoinjectors in the FDA-DOD Shelf Life Extension Program (SLEP).
    Khan SR; Mohammad A; Khan MA; Faustino PJ
    AAPS J; 2016 Jul; 18(4):801-3. PubMed ID: 27170033
    [No Abstract]   [Full Text] [Related]  

  • 5. A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates.
    Zilker M; Sörgel F; Holzgrabe U
    J Pharm Biomed Anal; 2019 Mar; 166():222-235. PubMed ID: 30660807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Shelf-life estimation of pharmaceutical products by matrixing].
    Yoshioka S; Aso Y; Kojima S
    Eisei Shikenjo Hokoku; 1996; (114):143-4. PubMed ID: 9037887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality.
    Fisher AC; Lee SL; Harris DP; Buhse L; Kozlowski S; Yu L; Kopcha M; Woodcock J
    Int J Pharm; 2016 Dec; 515(1-2):390-402. PubMed ID: 27773853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization.
    Novack GD; Evans R
    J Glaucoma; 2001 Dec; 10(6):483-6. PubMed ID: 11740219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the performance of the ICH guidelines for shelf life estimation.
    Quinlan M; Stroup W; Schwenke J; Christopher D
    J Biopharm Stat; 2013; 23(4):881-96. PubMed ID: 23786363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shelf-life extension program (SLEP) as a significant contributor to Strategic National Stockpile Maintenance: the Israeli experience with ciprofloxacin.
    Bodas M; Yuval L; Zadok R; Hess Z; Haran B; Kaplan M; Eisenkraft A
    Biosecur Bioterror; 2012 Jun; 10(2):182-7. PubMed ID: 22578017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming regulatory science 2012: making a difference.
    Goodman JL
    Clin Pharmacol Ther; 2012 Mar; 91(3):375-7. PubMed ID: 22343811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One- and two-stage Arrhenius models for pharmaceutical shelf life prediction.
    Fan Z; Zhang L
    J Biopharm Stat; 2015; 25(2):307-16. PubMed ID: 25358076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing distributions of shelf lives for drug products with two components under different designs.
    Pon A; Raghavarao D
    J Biopharm Stat; 2002 Aug; 12(3):277-93. PubMed ID: 12448571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of temperature-controlled requirements into pharmacy practice.
    Ziance R; Chandler C; Bishara RH
    J Am Pharm Assoc (2003); 2009; 49(3):e61-7; quiz e68-9. PubMed ID: 19443313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard Preparations, Limits of Potency, and Dating Period Limitations for Biological Products. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 May; 81(86):26687-92. PubMed ID: 27192727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Container-content compatibility studies: a pharmaceutical team's integrated approach.
    Laschi A; Sehnal N; Alarcon A; Barcelo B; Caire-Maurisier F; Delaire M; Feuilloley M; Genot S; Lacaze C; Pisarik L; Smati C
    PDA J Pharm Sci Technol; 2009; 63(4):285-93. PubMed ID: 20088243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of the shelf-life of drugs with mixed effects models.
    Chen JJ; Hwang JS; Tsong Y
    J Biopharm Stat; 1995 Mar; 5(1):131-40. PubMed ID: 7613558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug defect reporting program.
    Valentino JG
    Bull Parenter Drug Assoc; 1975; 29(2):55-63. PubMed ID: 1120213
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigation into the dissolution rate increase on storage of Wellbutrin SR 100 mg tablets.
    Wells ML; Williams SO; Sanftleben RA; Balik SB; Evans BA
    AAPS PharmSciTech; 2010 Mar; 11(1):113-9. PubMed ID: 20066523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.